Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced Pancreatic Cancer with BRCAness
NCT02511223Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Jul 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sheba Medical Center. Started Jul 2016; status: completed.
02
Drugs
olaparib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02511223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511223.